This is general information, not medical advice. Treatment decisions belong with your GP, respiratory nurse or consultant. Never stop or change prescribed medicines without professional guidance. In an emergency, call 999.
1. Executive summary
Five developments from this week that may matter most to people living with COPD in the UK:
1. NICE recommends the first biologic for COPD on the NHS
Dupilumab (Dupixent) received a positive NICE recommendation in March 2026 and is being commissioned as an add-on treatment for some adults with uncontrolled COPD and raised blood eosinophils. It is given as a self-injection every two weeks. Trial evidence reported fewer flare-ups than placebo. NHS England has estimated it could help up to 30,000 people in England.
Why this may matter: if frequent exacerbations continue despite inhalers, a respiratory team can advise whether an eosinophil blood test and specialist review are relevant. This is not a treatment everybody with COPD will be offered.
2. Targeted lung denervation trial at Royal Brompton Hospital
The first UK patients have received Targeted Lung Denervation (TLD) at Royal Brompton Hospital in London, as part of the AIRFLOW-1 clinical trial. The one-off bronchoscopic procedure uses energy to interrupt overactive lung nerves that can tighten airways and increase mucus. One participant described being noticeably less breathless afterwards.
Why this may matter: this is a research procedure, not routine NHS care. A consultant can advise whether a trial referral is appropriate for moderate-to-severe COPD.
3. New BTS framework to expand NHS pulmonary rehabilitation
The British Thoracic Society published a framework in March 2026 to help NHS services expand pulmonary rehabilitation. Rehabilitation remains one of the most useful non-drug supports for COPD, aiming to improve fitness, breathing confidence and quality of life.
Why this may matter: if you have not been referred, ask your GP or respiratory team. NHS programmes often run twice a week for at least six weeks and are free.
4. SPACE for COPD self-management programme
A UK trial published in Thorax (April 2026) reported that SPACE for COPD — a self-management programme combining activity, coping strategies and education — was clinically useful and cost-effective in UK settings.
Why this may matter: ask your respiratory team whether SPACE for COPD, or a similar home and community programme, is available locally.
5. UK clinical trials still recruiting
Sites including Glasgow and London are recruiting people with COPD through research organisations such as FutureMeds and the British Research Panel, alongside hospital-led studies such as AIRFLOW-1.
Why this may matter: trials can offer closer monitoring and access to investigational treatments, but they also carry risks and may include placebo. Discuss any study thoroughly with your own clinician before joining.
2. UK research in more detail
Dupilumab (Dupixent) — first biologic for COPD in the UK
What was reported: NICE technology appraisal TA1142 recommends dupilumab as an add-on maintenance treatment for some adults with uncontrolled COPD and raised blood eosinophils.
- How it works: a monoclonal antibody that blocks IL-4 and IL-13 inflammatory pathways involved in eosinophilic COPD, rather than broadly suppressing inflammation.
- How it is given: self-administered every two weeks with an autoinjector after initial training. Ongoing hospital visits are not always required.
- Evidence: the BOREAS trial reported about a 30% reduction in exacerbations; the NOTUS trial reported about 34%, compared with placebo.
- Who may be considered: adults who still have exacerbations despite optimised inhaled therapy (often LABA/LAMA/ICS) and who have raised blood eosinophils on a blood test. Eligibility is a clinical decision.
- NHS access: NHS England published business-case guidance for Integrated Care Boards. A commercial access agreement is in place with Sanofi. Estimates suggest it could help up to 30,000 people in England, depending on local commissioning.
- Cost: list price is reported as £1,264.89 per dose; the NHS pays a confidential discounted price.
This is the first biologic treatment for COPD recommended for NHS use. It is a targeted option for a specific group of people, not a replacement for inhalers for everyone.
Questions you may wish to take to an appointment:
- Have I had a recent blood eosinophil test, and what did it show?
- If I still have flare-ups on triple inhaled therapy, would a specialist review for biologics be appropriate?
- Has my local Integrated Care Board started commissioning this service, and what is the referral route?
More information: NICE TA1142 · NHS England biologics guidance
Targeted Lung Denervation — first UK patients at Royal Brompton
What was reported: the first UK patients have undergone Targeted Lung Denervation at Royal Brompton Hospital, London, as part of the international AIRFLOW-1 trial.
- How it works: under general anaesthetic, a bronchoscope delivers controlled energy to selected branches of the vagus nerve in the lungs — nerves involved in airway muscle contraction and mucus production, which can be overactive in COPD.
- The procedure: minimally invasive, around one hour, designed as a one-off treatment. Lasting benefit is still being studied.
- Patient account: Gillian Joseph, 72, from Bushey, Hertfordshire, who has lived with emphysema for 18 years, said: “I was noticeably less breathless immediately after having the treatment. Now I can go shopping and walk around normally for the first time in years — it feels like a miracle.” Individual results vary and should not be read as a promise of the same outcome.
- Who is being studied: people with moderate to severe COPD, in a trial at Royal Brompton in collaboration with Chelsea and Westminster Hospital.
This remains a research procedure at a specialist centre, not standard local care. A respiratory consultant can advise whether a trial discussion is suitable.
More information: Royal Brompton Hospital — TLD news
BTS framework to expand pulmonary rehabilitation
The British Thoracic Society published a framework aimed at expanding pulmonary rehabilitation capacity across the NHS. The Royal College of Physicians also provides a capacity-planning tool for services. NHS England’s COPD commissioning guidance continues to treat rehabilitation as a core intervention.
- Typical NHS programmes: two or more group sessions a week for at least six weeks, including exercise, breathing techniques, education and nutrition advice.
- The BTS quality standard recommends that people who complete a programme receive a personalised ongoing exercise plan.
Pulmonary rehabilitation can improve exercise capacity, reduce breathlessness for some people, and support confidence. Access still varies by area, so asking about referral remains important.
More information: NHS COPD treatment · BTS framework announcement · Wheezy Does It rehabilitation guide
SPACE for COPD — self-management programme
A UK randomised controlled trial reported that SPACE for COPD (Self-management Programme of Activity, Coping and Education) was clinically useful and cost-effective. It combines physical-activity guidance, breathlessness coping strategies and COPD education, and is designed for community and home use rather than hospital attendance.
Ask your GP, respiratory nurse or rehabilitation team whether SPACE for COPD, or another structured self-management programme, is offered locally.
More information: PubMed — SPACE for COPD trial
UK clinical trials recruiting people with COPD
- FutureMeds: COPD trials in Glasgow, London and other UK cities, typically looking for people diagnosed with COPD, with a smoking history, who have had exacerbations. Participants may receive investigational treatment or placebo, regular monitoring, and reimbursement for visits.
- British Research Panel: a free registry that can send invitations for studies.
- AIRFLOW-1 (TLD): Royal Brompton Hospital, London.
Joining a trial is a personal decision. Ask your consultant about studies at your local NHS trust, and read patient information sheets carefully.
More information: FutureMeds COPD trials · British Research Panel
NHS and Asthma + Lung UK resources
- NHS COPD treatment pages cover pulmonary rehabilitation, inhaled medicines, oxygen therapy and, for some people, surgery.
- NHS living-with-COPD guidance includes pursed-lip breathing, relaxed slow breathing, and breathing in rhythm with activity.
- NHS Inform Scotland highlights exercise, walking groups and singing groups, which some people find help respiratory muscle use.
- Asthma + Lung UK offers information, a helpline and local support groups.
NHS treatment · NHS living with COPD · NHS Inform — exercising with COPD · Asthma + Lung UK
3. Practical health strategies
Evidence-informed ideas to discuss with your healthcare team. They are not a substitute for your own COPD action plan.
Breathing techniques
- Pursed-lip breathing: breathe in through the nose for a count of two, then out through pursed lips for a count of four. This can help keep airways open a little longer. Practise for short periods several times a day if it feels comfortable.
- Diaphragmatic breathing: aim for the belly to rise more than the upper chest, if this is taught as suitable for you.
- Huff coughing: a deep breath followed by a forceful “huff” can help move mucus with less strain than hard coughing.
- Singing groups: NHS Scotland notes that some singing groups may support respiratory muscle use.
Exercise and pulmonary rehabilitation
- Moderate activity such as walking, cycling or swimming for 20–30 minutes, three to four times a week, is often recommended if it is safe for you.
- If oxygen is prescribed, using it as advised during activity can be more helpful than exercise or oxygen alone for some people.
- Ask about NHS pulmonary rehabilitation — typically twice a week for six weeks or more.
- Resistance training twice a week may support muscle strength, including muscles used for breathing.
- Ask for a personalised exercise plan after completing rehabilitation, in line with BTS quality standards.
Medicines and treatment questions
- Ask whether your treatment is in line with current GOLD and NICE guidance for your situation.
- Ask about a blood eosinophil test if flare-ups continue on inhaled therapy.
- Ask a consultant whether specialist procedures or trials, including AIRFLOW-1, are relevant.
- Ask about SPACE for COPD or another self-management programme.
Nutrition and hydration
- Staying hydrated can help keep mucus thinner and easier to clear.
- Smaller, more frequent meals can reduce pressure on the diaphragm.
- Anti-inflammatory eating patterns often include oily fish, leafy greens, berries, nuts and olive oil — discuss personal dietary needs first.
- Both low weight and high weight can make COPD harder to manage. Adequate protein supports muscle strength.
Home and air quality
- Check UK air quality at uk-air.defra.gov.uk and on our Air-Quality dashboard.
- Some people use a HEPA purifier in the bedroom or main living space.
- Keeping indoor humidity around 30–50% may reduce mould and dust mites.
- A home pulse oximeter can help you record oxygen readings if your team has shown you how to use one. Typical pharmacy prices are around £15–20.
- Good kitchen ventilation can reduce cooking fumes, which trigger symptoms for some people.
Mental health and support
- Anxiety and low mood are common with COPD and can make breathing feel worse. They deserve care in their own right.
- Relaxation and mindfulness practices help some people with breathlessness-related anxiety.
- Support groups can reduce isolation.
- Ask your GP about NHS Talking Therapies if mood or worry is affecting daily life.
4. Wider international research
Significant developments worldwide, with a note on whether they may reach UK practice.
GOLD 2026 report
The Global Initiative for Chronic Obstructive Lung Disease 2026 report adds biologics (dupilumab and mepolizumab) as add-on options, introduces a “disease activity” monitoring idea, updates case-finding guidance, designates triple therapy for Group E patients, and formally acknowledges digital health tools.
UK note: NICE has already recommended dupilumab. Mepolizumab may follow. Disease-activity tracking could influence how NHS teams monitor COPD over time.
Mepolizumab (Nucala) — a second biologic
This medicine targets the IL-5 pathway, rather than dupilumab’s IL-4/IL-13 pathway. GOLD 2026 lists it as another biologic option for eosinophilic COPD. A different mechanism means it may be considered for people who do not respond to dupilumab, if and when it is approved for this use in the UK.
UK note: NICE evaluation is expected. NHS England biologics guidance has noted that further biologic therapies are likely. Timing is uncertain.
Stem cell therapy — early trials
SMSbiotech has started a Phase 1 human trial (SORT-COPD, NCT06986070) using small mobile stem cells. Other early studies of progenitor cells report safety signals and, in some people with severe emphysema, measured changes after a few months. These findings are preliminary.
UK note: experimental. UK recruitment is not widely available. Larger trials would be needed before any routine NHS use could be considered, likely years away.
Gene therapy and CRISPR approaches
Research includes CRISPR-based work on alpha-1 antitrypsin deficiency, CFTR modulators for some COPD subtypes, and gene therapies aiming to deliver functioning genes to lung cells.
UK note: early-stage. If COPD is linked to a genetic condition such as alpha-1 antitrypsin deficiency, ask about genetic testing. Targeted therapies, if they arrive, may do so first for that smaller group.
Ohtuvayre (ensifentrine)
A US FDA-approved maintenance treatment with a dual action: bronchodilation and anti-inflammatory effect. It is a different class from existing bronchodilators and steroids.
UK note: European and UK evaluation is anticipated. Availability on the NHS is not guaranteed and would depend on licensing and NICE appraisal.
AI-supported smart inhalers
Bluetooth-connected inhalers can track doses, adherence and, in some systems, combine that data with activity or air-quality information. Some studies report fewer exacerbations. The European Respiratory Society offers professional training on digital health in COPD.
UK note: some connected inhaler devices are already available. Ask a GP, pharmacist or respiratory team what is offered locally. Some NHS trusts are piloting digital COPD monitoring.
Oxygen therapy plus exercise
A Frontiers in Medicine meta-analysis reported that long-term oxygen therapy combined with exercise rehabilitation was more effective than exercise alone for some measures of capacity, lung function and quality of life. Personalised oxygen approaches and high-flow nasal cannula are also being studied.
UK note: relevant to NHS practice where oxygen is already prescribed. Discuss combined exercise and oxygen plans with your respiratory team rather than changing oxygen use yourself.
Advanced bronchoscopic procedures
Beyond TLD, research continues on endobronchial valves, robotic lung-volume reduction and polymer implants. These aim for surgical-level benefit without open surgery, for carefully selected people.
UK note: endobronchial valves are already offered at some specialist UK centres. Ask a pulmonologist whether referral to a specialist respiratory centre is appropriate.
5. Sources
UK sources
- NICE — TA1142: Dupilumab for COPD (March 2026)
- NHS England — Business case guidance for COPD biologics
- Royal Brompton Hospital — First UK patients receive TLD treatment
- British Thoracic Society — Framework for pulmonary rehabilitation (March 2026)
- Thorax — SPACE for COPD clinical and cost-effectiveness trial
- NHS.uk — COPD treatment · Living with COPD
- NHS Inform Scotland — Exercising with COPD
- Asthma + Lung UK — COPD information and support
- NHS England — COPD commissioning strategies
- FutureMeds — UK COPD clinical trials
- British Research Panel — COPD study recruitment
- Pharmaphorum — COPD patients and Dupixent via the NHS
- BMJ — New targeted treatment approved by NICE
- Royal College of Physicians — Pulmonary rehabilitation capacity planning tool
International sources
- GOLD 2026 — Transforming COPD management · GOLD report and pocket guide
- Pulmonology Advisor — GOLD COPD update 2026
- Healio — 2026 GOLD report: disease activity and technology
- ClinicalTrials.gov — NCT06986070: SORT-COPD stem cell trial
- DVC Stem — COPD treatment round-up
- Doctronic — New COPD treatments 2026
- Frontiers in Medicine — Meta-analysis: long-term oxygen plus exercise
- ScienceDirect — Exercise interventions and oxygen uptake in COPD
- Washington University — Portable oxygen in COPD
- Cleveland Clinic — Breathing exercises for COPD
- European Respiratory Society — Digital health, AI and smart inhalers
- DelveInsight — Smart inhalers in respiratory care
- Medrac (UNC) — Ohtuvayre (ensifentrine)
- Policy Lab — COPD clinical trials and research
Medical disclaimer: This digest is for information only. It does not diagnose, prescribe or replace advice from a qualified healthcare professional. Clinical trial participation carries risks. Always discuss treatment changes with your own COPD team. Call 999 for severe breathing difficulty, blue or grey lips or skin, chest pain or sudden confusion.